MedPath

Verona Pharma Announces Publication of Key Phase 2b ...

Ensifentrine, a novel inhaled dual phosphodiesterase 3 and 4 inhibitor, showed significant improvements in lung function and COPD symptoms in Phase 2b trials, offering potential as a first-in-class therapy combining bronchodilator and anti-inflammatory effects.


Reference News

Verona Pharma Announces Publication of Key Phase 2b ...

Ensifentrine, a novel inhaled dual phosphodiesterase 3 and 4 inhibitor, showed significant improvements in lung function and COPD symptoms in Phase 2b trials, offering potential as a first-in-class therapy combining bronchodilator and anti-inflammatory effects.

© Copyright 2025. All Rights Reserved by MedPath